Safety and Survival Benefit of Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colon Cancer.

IF 1.7 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2025-02-01 DOI:10.21873/anticanres.17468

In Jun Yang, Dong Ha Kim, Kyung-Ha Lee, Ji Yeon Kim

{"title":"Safety and Survival Benefit of Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colon Cancer.","authors":"In Jun Yang, Dong Ha Kim, Kyung-Ha Lee, Ji Yeon Kim","doi":"10.21873/anticanres.17468","DOIUrl":null,"url":null,"abstract":"Background/aim: To evaluate the safety and survival benefits of adjuvant chemotherapy (AC) in elderly patients who underwent radical resection for stage II/III colon cancer.Patients and methods: This retrospective study included patients aged >70 years treated at a tertiary hospital between January 2012 and December 2017. We evaluated the clinical and pathological characteristics and adverse events of chemotherapy. The 5-year overall survival (OS) and disease-free survival (DFS) of the surgery-only (SO) and AC groups were compared by stage using the Kaplan-Meier method and Cox-regression analysis.Results: Of the 163 patients included in the study, 75 were diagnosed with stage II cancer, with 43 patients in the SO group and 32 in the AC group. A total of 88 patients were diagnosed with stage III cancer, including 20 in the SO group and 68 in the AC group. Patients with stage II disease in the SO group were older, with less frequent venous invasion than the AC group. Comorbidities, tumor location, and surgical methods did not differ. In stage III, age, comorbidities, tumor location, surgical methods, and pathological outcomes did not differ. The 5-year OS and DFS did not differ significantly in those with stage II disease but were significantly better in the AC than the SO group in stage III cases (48.2% vs. 71.6%, p=0.012; and 42.6% vs. 60.0%, p=0.029).Conclusion: AC may provide a survival advantage in elderly patients with stage III colon cancer.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 2","pages":"797-809"},"PeriodicalIF":1.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17468","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: To evaluate the safety and survival benefits of adjuvant chemotherapy (AC) in elderly patients who underwent radical resection for stage II/III colon cancer.

Patients and methods: This retrospective study included patients aged >70 years treated at a tertiary hospital between January 2012 and December 2017. We evaluated the clinical and pathological characteristics and adverse events of chemotherapy. The 5-year overall survival (OS) and disease-free survival (DFS) of the surgery-only (SO) and AC groups were compared by stage using the Kaplan-Meier method and Cox-regression analysis.

Results: Of the 163 patients included in the study, 75 were diagnosed with stage II cancer, with 43 patients in the SO group and 32 in the AC group. A total of 88 patients were diagnosed with stage III cancer, including 20 in the SO group and 68 in the AC group. Patients with stage II disease in the SO group were older, with less frequent venous invasion than the AC group. Comorbidities, tumor location, and surgical methods did not differ. In stage III, age, comorbidities, tumor location, surgical methods, and pathological outcomes did not differ. The 5-year OS and DFS did not differ significantly in those with stage II disease but were significantly better in the AC than the SO group in stage III cases (48.2% vs. 71.6%, p=0.012; and 42.6% vs. 60.0%, p=0.029).

Conclusion: AC may provide a survival advantage in elderly patients with stage III colon cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

老年II/III期结肠癌患者辅助化疗的安全性和生存获益

背景/目的：评价高龄II/III期结肠癌根治术患者辅助化疗（AC）的安全性和生存获益。患者和方法：本回顾性研究纳入2012年1月至2017年12月在某三级医院治疗的年龄在bb0 ~ 70岁的患者。我们评估了化疗的临床病理特点和不良事件。采用Kaplan-Meier法和cox回归分析，分阶段比较单纯手术组（SO）和单纯手术组（AC）的5年总生存期（OS）和无病生存期（DFS）。结果：在纳入研究的163例患者中，75例被诊断为II期癌症，其中SO组43例，AC组32例。共有88例患者被诊断为III期癌症，其中SO组20例，AC组68例。与AC组相比，SO组II期患者年龄更大，静脉侵入频率更低。合并症、肿瘤位置和手术方法没有差异。在III期，年龄、合并症、肿瘤位置、手术方法和病理结果没有差异。II期患者的5年OS和DFS无显著差异，但AC组III期患者的5年OS和DFS明显优于SO组(48.2% vs 71.6%, p=0.012；42.6% vs. 60.0%, p=0.029)。结论：AC可能为老年III期结肠癌患者提供生存优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.